Eli Lilly and Company
IL-17A INHIBITORS
Last updated:
Abstract:
The invention provides certain difluorocyclohexyl-imidazopyridazinyl-imidazolidinone compounds of formula II as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula II to treat certain symptoms of psoriasis, rheumatoid arthritis or multiple sclerosis. ##STR00001##
Status:
Application
Type:
Utility
Filling date:
3 Jan 2020
Issue date:
10 Mar 2022